Abstract
Background: Evidence-based best practices for risk stratification of elderly breast cancer patients are still lacking. Data for this patient population are scarce since elderly patients are underrepresented in clinical oncology trials. As a result, lower doses of chemotherapy are prescribed due to concerns for cardiotoxicity, frailty and high prevalence of multimorbidity [1]. This contributes to undertreatment and suboptimal outcomes with a negative impact on the patients’ Quality of Life (QoL) [2].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
